Tandem Diabetes Care (TNDM) Set to Announce Earnings on Wednesday

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) is set to announce its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Tandem Diabetes Care has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Persons that are interested in registering for the company's earnings conference call can do so using this link.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its earnings results on Thursday, August 1st. The medical device company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07. The firm had revenue of $221.90 million for the quarter, compared to the consensus estimate of $205.63 million. Tandem Diabetes Care had a negative net margin of 17.15% and a negative return on equity of 41.54%. The business's quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the company posted ($0.30) EPS. On average, analysts expect Tandem Diabetes Care to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tandem Diabetes Care Stock Down 1.7 %

Shares of Tandem Diabetes Care stock traded down $0.57 on Wednesday, hitting $32.36. The company had a trading volume of 782,309 shares, compared to its average volume of 1,590,265. Tandem Diabetes Care has a twelve month low of $13.82 and a twelve month high of $53.69. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.05 and a quick ratio of 2.38. The stock has a 50-day moving average of $40.57 and a 200-day moving average of $41.91. The firm has a market capitalization of $2.12 billion, a P/E ratio of -15.76 and a beta of 1.33.

Analyst Ratings Changes

A number of brokerages have recently commented on TNDM. Canaccord Genuity Group initiated coverage on shares of Tandem Diabetes Care in a research report on Thursday, August 8th. They issued a "buy" rating and a $57.00 price objective on the stock. Wells Fargo & Company lifted their price target on shares of Tandem Diabetes Care from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Friday, August 2nd. Piper Sandler restated an "overweight" rating and issued a $55.00 price objective (up previously from $50.00) on shares of Tandem Diabetes Care in a report on Friday, August 2nd. UBS Group raised Tandem Diabetes Care to a "hold" rating in a research report on Friday, August 2nd. Finally, Robert W. Baird increased their price target on Tandem Diabetes Care from $36.00 to $39.00 and gave the company a "neutral" rating in a research report on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of "Moderate Buy" and a consensus price target of $55.13.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.